LOS ANGELES – JUNE 5, 2025 – MedTech Innovator (MTI), the world’s largest and most impactful accelerator for medical technology startups, today announced the 65 companies selected for its highly competitive 2025 Accelerator Cohort. These companies, representing the top 4% of nearly 1,500 global applicants, will participate in MTI’s flagship four-month program designed to de-risk innovation and accelerate the path to U.S. market success.
The 2025 cohort includes early and mid-stage medical device, diagnostic, and digital health companies that will receive unparalleled mentorship, strategic guidance, and access to MTI’s world-class ecosystem of industry-leading strategic manufacturers, investors, providers, payers, patients, and other industry stakeholders. Participants also join the highest-performing peer network in the sector. MTI alumni have collectively brought over 400 products to market and raised $10 billion in follow-on funding. Companies in this year’s cohort will compete for a share of $800,000 in non-dilutive funding, with winners selected by audience vote at major industry conferences.
“MedTech Innovator’s accelerator is a comprehensive platform for risk mitigation and value creation that helps the world’s most promising medtech startups become investable,” said Paul Grand, CEO and founder. “Over the next four months, our 2025 cohort will work closely with MTI’s extensive network of mentors and partners to advance these innovative technologies toward U.S. market access and public health benefit.”
Following a rigorous evaluation process, MTI and its corporate partners invited 213 companies (15 percent of applicants) to pitch at this year’s MedTech Innovator Road Tour events in Los Angeles, College Park, Md., and Dublin. The 65 selected cohort companies received feedback from 430 subject matter experts and represent 17 U.S. states and 13 countries.
